Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranor
December 06, 2021 16:00 ET
|
INVENTIVA
Etude conduite chez 217 volontaires sains afin d’évaluer l’effet de lanifibranor sur l’intervalle QT/QTc et de soutenir la demande d’enregistrement d’un nouveau médicament (New Drug Application...
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
December 06, 2021 16:00 ET
|
INVENTIVA
Trial conducted in 217 patients to evaluate the potential effect of lanifibranor on the QT/QTc interval in healthy subjects and to support lanifibranor New Drug Application (NDA) package in NASH ...
PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD - The Liver Meeting Digital Experience™ (TLMdX) 2021
November 12, 2021 08:00 ET
|
PHARMANEST
PRINCETON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PharmaNest is a digital pathology and artificial intelligence company that is focused on the development and validation of novel standards for...
Inventiva publie ses informations financières du 3ème trimestre 2021
November 10, 2021 16:00 ET
|
INVENTIVA
Trésorerie et équivalents de trésorerie à 105,7 M€ au 30 septembre 2021 Chiffre d’affaires de 0,2 M€ sur les neuf premiers mois de 2021 Daix (France), Long Island City (New York, United States),...
Inventiva reports 2021 Third Quarter Financial Information
November 10, 2021 16:00 ET
|
INVENTIVA
Cash and cash equivalents at €105.7m as of September 30, 2021Revenues of €0.2m for the first nine months of 2021 Daix (France), Long Island City (New York, United States), November 10, 2021 –...
Inventiva organise un webcast avec des leaders d’opinion à l’occasion du congrès The Liver Meeting™ 2021 de l’AASLD
November 03, 2021 16:00 ET
|
INVENTIVA
Revue par les Prof. Nezam Afdhal et Jörn Schattenberg de cinq abstracts présentés lors du The Liver Meeting™ 2021 de l’AASLDPoint sur le secteur de la NASH par le Prof. Nezam AfdhalPoint d’étape par...
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021
November 03, 2021 16:00 ET
|
INVENTIVA
Presentation of five scientific abstracts selected for poster presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam Afdhal and Prof. Jörn SchattenbergUpdate on the current NASH landscape...
Inventiva annonce le design de LEGEND, un essai clinique de Phase IIa combinant lanifibranor et empagliflozine, un inhibiteur du SGLT2, chez des patients atteints de la NASH et de diabète de type 2
October 27, 2021 16:00 ET
|
INVENTIVA
L’essai clinique LEGEND est un essai de Phase IIa de preuve de concept visant à évaluer la sécurité et l'efficacité de lanifibranor en combinaison avec empagliflozine, un inhibiteur du co-transporteur...
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
October 27, 2021 16:00 ET
|
INVENTIVA
The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy of lanifibranor in combination with the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
October 20, 2021 17:07 ET
|
INVENTIVA
In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of...